基本信息

产品名称	Nimacimab (anti-CNR1), 大麻素 CB1 受体负异位调节剂的负异位调节剂
别名	尼马昔单抗(抗 CNR1)
英文别名	CANN6 \| CB1 \| CB-R
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	CNR1
种属反应性	人(Human),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	负变构调节剂
作用机制	大麻素 CB1 受体负异位调节剂的负异位调节剂

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG4SP
轻链亚型	kappa
SDS-PAGE	26.3 kDa (Light Chain) & 51.7 kDa (Heavy Chain), under reducing conditions; 186.2 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	2098636-09-8
分子类型	抗体

图片

ELISA: Nimacimab (anti-CNR1) (Ab177882)

Nimacimab (anti-CNR1) (Ab177882) - ELISA
Immobilized Hu-CNR1 at 2 μg/mL can bind Nimacimab (anti-CNR1) (Ab177882) with the EC₅₀ of 16.71ng/mL.

SEC: Nimacimab (anti-CNR1) (Ab177882)

Nimacimab (anti-CNR1) (Ab177882) - SEC
The purity of Nimacimab (anti-CNR1) (Ab177882) is more than 95% verified by HPLC.

关联靶点（人）

CNR1 Tclin 大麻素受体 1(Cannabinoid receptor 1) (0 活性数据)

点击查看靶蛋白信息： CNR1

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

CNR1 Tclin Cannabinoid CB1 receptor (20913 活性数据)

点击查看靶蛋白信息： CNR1

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

CNR1 Tclin Cannabinoid CB1 receptor/orexin receptor 1 complex (18 活性数据)

点击查看靶蛋白信息： CNR1

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F0404130	分析证书	24-04-03	Ab177882
ZJ24F0404129	分析证书	24-04-03	Ab177882
ZJ24F0404128	分析证书	24-04-03	Ab177882

可替换产品

参考文献

1. Gérard C, Mollereau C, Vassart G, Parmentier M. (1990) Nucleotide sequence of a human cannabinoid receptor cDNA.. Nucleic Acids Res, 18 (23): (7142). [PMID:2263478]
2. Bouaboula M, Bourrié B, Rinaldi-Carmona M, Shire D, Le Fur G, Casellas P. (1995) Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells.. J Biol Chem, 270 (23): (13973-80). [PMID:7775459]
3. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D, Ferrara P. (1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing.. J Biol Chem, 270 (8): (3726-31). [PMID:7876112]
4. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessègue B, Bonnin-Cabanne O, Le Fur G, Caput D, Ferrara P. (1996) Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.. Biochim Biophys Acta, 1307 (2): (132-6). [PMID:8679694]
5. Gérard CM, Mollereau C, Vassart G, Parmentier M. (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis.. Biochem J, 279 ( Pt 1) (129-34). [PMID:1718258]
6. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH et al.. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.. Nat Chem Biol, 5 (1): (37-44). [PMID:19029917]
7. Cappelli A, Manini M, Valenti S, Castriconi F, Giuliani G, Anzini M, Brogi S, Butini S, Gemma S, Campiani G et al.. (2013) Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.. Eur J Med Chem, 63 (85-94). [PMID:23466604]
8. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR et al.. (2008) cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.. J Med Chem, 51 (22): (7094-8). [PMID:18983139]
9. Mattmann ME, Yu H, Lin Z, Xu K, Huang X, Long S, Wu M, McManus OB, Engers DW, Le UM et al.. (2012) Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.. Bioorg Med Chem Lett, 22 (18): (5936-41). [PMID:22910039]
10. Zhou G, Zorn N, Ting P, Aslanian R, Lin M, Cook J, Lachowicz J, Lin A, Smith M, Hwa J et al.. (2014) Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.. ACS Med Chem Lett, 5 (5): (544-9). [PMID:24900877]
11. Coombs TC, Tanega C, Shen M, Wang JL, Auld DS, Gerritz SW, Schoenen FJ, Thomas CJ, Aubé J. (2013) Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.. Bioorg Med Chem Lett, 23 (12): (3654-61). [PMID:23642479]
12. Gentry PR, Kokubo M, Bridges TM, Noetzel MJ, Cho HP, Lamsal A, Smith E, Chase P, Hodder PS, Niswender CM et al.. (2014) Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380).. J Med Chem, 57 (18): (7804-10). [PMID:25147929]
13. Sharma MK, Murumkar PR, Barmade MA, Giridhar R, Yadav MR. (2015) A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents.. Expert Opin Ther Pat, 25 (10): (1093-116). [PMID:26161824]
14. Migliore M, Habrant D, Sasso O, Albani C, Bertozzi SM, Armirotti A, Piomelli D, Scarpelli R. (2016) Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.. Eur J Med Chem, 109 (216-37). [PMID:26774927]
15. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A et al.. (2008) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.. Cell Metab, 7 (1): (68-78). [PMID:18177726]
16. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O et al.. (2004) SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.. J Pharmacol Exp Ther, 310 (3): (905-14). [PMID:15131245]
17. Laprairie RB, Kulkarni AR, Kulkarni PM, Hurst DP, Lynch D, Reggio PH, Janero DR, Pertwee RG, Stevenson LA, Kelly ME et al.. (2016) Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.. ACS Chem Neurosci, 7 (6): (776-98). [PMID:27046127]
18. Kulkarni PM, Kulkarni AR, Korde A, Tichkule RB, Laprairie RB, Denovan-Wright EM, Zhou H, Janero DR, Zvonok N, Makriyannis A et al.. (2016) Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).. J Med Chem, 59 (1): (44-60). [PMID:26529344]
19. Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, Zhao S, Shui W, Li S, Korde A et al.. (2016) Crystal Structure of the Human Cannabinoid Receptor CB1.. Cell, 167 (3): (750-762.e14). [PMID:27768894]
20. Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J, Rosenbaum DM. (2016) High-resolution crystal structure of the human CB1 cannabinoid receptor.. Nature, 540 (7634): (602-606). [PMID:27851727]
21. Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho JH et al.. (2017) Crystal structures of agonist-bound human cannabinoid receptor CB₁.. Nature, 547 (7664): (468-471). [PMID:28678776]
22. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J et al.. (2010) Spiroindolones, a potent compound class for the treatment of malaria.. Science, 329 (5996): (1175-80). [PMID:20813948]
23. Han S, Thatte J, Buzard DJ, Jones RM. (2013) Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.. J Med Chem, 56 (21): (8224-56). [PMID:23865723]
24. Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, Mitton-Fry MJ, Johnson TA, TenBrink RE, Arnold EP et al.. (2018) Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.. J Med Chem, 61 (3): (1130-1152). [PMID:29298069]
25. Bowles NP, Karatsoreos IN, Li X, Vemuri VK, Wood JA, Li Z, Tamashiro KL, Schwartz GJ, Makriyannis AM, Kunos G et al.. (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome.. Proc Natl Acad Sci USA, 112 (1): (285-90). [PMID:25535367]
26. Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Luz Bellido M, Ortega-Castro R, Pérez-Sánchez C et al.. (2018) VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB₂ receptor-dependent pathways.. Br J Pharmacol, 175 (19): (3813-3831). [PMID:30033591]
27. Appendino G, Cascio MG, Bacchiega S, Moriello AS, Minassi A, Thomas A, Ross R, Pertwee R, De Petrocellis L, Di Marzo V. (2006) First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands.. FEBS Lett, 580 (2): (568-74). [PMID:16406364]
28. Cinar R, Iyer MR, Liu Z, Cao Z, Jourdan T, Erdelyi K, Godlewski G, Szanda G, Liu J, Park JK et al.. (2016) Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.. JCI Insight, 1 (11): [PMID:27525312]
29. Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, Mukhopadhyay B, Chedester L, Liow JS et al.. (2012) Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance.. Cell Metab, 16 (2): (167-79). [PMID:22841573]
30. Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, Wehn PM, Yang H, Dixon DD et al.. (2019) 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.. J Med Chem, 62 (15): (6876-6893). [PMID:31282155]
31. Robert J Altenbach,Ronald M Adair,Brian M Bettencourt,Lawrence A Black,Shannon R Fix-Stenzel,Sujatha M Gopalakrishnan,Gin C Hsieh,Huaqing Liu,Kennan C Marsh,Michael J McPherson,Ivan Milicic,Thomas R Miller,Timothy A Vortherms,Usha Warrior,Jill M Wetter,Neil Wishart,David G Witte,Prisca Honore,Timothy A Esbenshade,Arthur A Hancock,Jorge D Brioni,Marlon D Cowart. (2008-09-25) Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.. Journal of medicinal chemistry, 51 ((20)): (6571-6580). [PMID:18811133]
32. Ganesh A Thakur,Shama Bajaj,Carol Paronis,Yan Peng,Anna L Bowman,Lawrence S Barak,Marc G Caron,Demon Parrish,Jeffrey R Deschamps,Alexandros Makriyannis. (2013-04-30) Novel adamantyl cannabinoids as CB1 receptor probes.. Journal of medicinal chemistry, 56 ((10)): (3904-3921). [PMID:23621789]
33. Alan Fulp,Katherine Bortoff,Yanan Zhang,Rodney Snyder,Tim Fennell,Julie A Marusich,Jenny L Wiley,Herbert Seltzman,Rangan Maitra. (2013-09-18) Peripherally selective diphenyl purine antagonist of the CB1 receptor.. Journal of medicinal chemistry, 56 ((20)): (8066-8072). [PMID:24041123]
34. Takayuki Fukaya,Takeo Ishiyama,Satoko Baba,Shuji Masumoto. (2013-09-21) Identification of a novel benzoxazolone derivative as a selective, orally active 18 kDa translocator protein (TSPO) ligand.. Journal of medicinal chemistry, 56 ((20)): (8191-8195). [PMID:24050790]
35. Matteo Gianella-Borradori,Ivy Christou,Carole J R Bataille,Rebecca L Cross,Graham M Wynne,David R Greaves,Angela J Russell. (2014-12-10) Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.. Bioorganic & medicinal chemistry, 23 ((1)): (241-263). [PMID:25487422]
36. Tobias Rogosch,Christian Sinning,Agnes Podlewski,Bernhard Watzer,Joel Schlosburg,Aron H Lichtman,Maria G Cascio,Tiziana Bisogno,Vincenzo Di Marzo,Rolf Nüsing,Peter Imming. (2011-12-17) Novel bioactive metabolites of dipyrone (metamizol).. Bioorganic & medicinal chemistry, 20 ((1)): (101-107). [PMID:22172309]
37. Alan Fulp,Katherine Bortoff,Yanan Zhang,Herbert Seltzman,James Mathews,Rodney Snyder,Tim Fennell,Rangan Maitra. (2012-10-27) Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists.. Journal of medicinal chemistry, 55 ((22)): (10022-10032). [PMID:23098108]
38. Margherita Brindisi,Samuele Maramai,Sandra Gemma,Simone Brogi,Alessandro Grillo,Lorenzo Di Cesare Mannelli,Emanuele Gabellieri,Stefania Lamponi,Simona Saponara,Beatrice Gorelli,Daniele Tedesco,Tommaso Bonfiglio,Christophe Landry,Kwang-Mook Jung,Andrea Armirotti,Livio Luongo,Alessia Ligresti,Fabiana Piscitelli,Carlo Bertucci,Marie-Pierre Dehouck,Giuseppe Campiani,Sabatino Maione,Carla Ghelardini,Anna Pittaluga,Daniele Piomelli,Vincenzo Di Marzo,Stefania Butini. (2016-02-19) Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain.. Journal of medicinal chemistry, 59 ((6)): (2612-2632). [PMID:26888301]
39. Muccioli GG, Wouters J, Charlier C, Scriba GK, Pizza T, Di Pace P, De Martino P, Poppitz W, Poupaert JH, Lambert DM.. (2006) Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.. J Med Chem, 49 (3): (872-882). [PMID:16451053] [10.1021/jm050484f]
40. Boström J, Berggren K, Elebring T, Greasley PJ, Wilstermann M.. (2007) Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.. Bioorg Med Chem, 15 (12): (4077-4084). [PMID:17433696] [10.1016/j.bmc.2007.03.075]
41. Smith RA, Fathi Z, Brown SE, Choi S, Fan J, Jenkins S, Kluender HC, Konkar A, Lavoie R, Mays R, Natoli J, O'Connor SJ, Ortiz AA, Podlogar B, Taing C, Tomlinson S, Tritto T, Zhang Z.. (2007) Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.. Bioorg Med Chem Lett, 17 (3): (673-678). [PMID:17107792] [10.1016/j.bmcl.2006.10.095]
42. Smith RA, Fathi Z, Achebe F, Akuche C, Brown SE, Choi S, Fan J, Jenkins S, Kluender HC, Konkar A, Lavoie R, Mays R, Natoli J, O'Connor SJ, Ortiz AA, Su N, Taing C, Tomlinson S, Tritto T, Wang G, Wirtz SN, Wong W, Yang XF, Ying S, Zhang Z.. (2007) Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.. Bioorg Med Chem Lett, 17 (10): (2706-2711). [PMID:17383180] [10.1016/j.bmcl.2007.03.011]
43. Alig L, Alsenz J, Andjelkovic M, Bendels S, Bénardeau A, Bleicher K, Bourson A, David-Pierson P, Guba W, Hildbrand S, Kube D, Lübbers T, Mayweg AV, Narquizian R, Neidhart W, Nettekoven M, Plancher JM, Rocha C, Rogers-Evans M, Röver S, Schneider G, Taylor S, Waldmeier P.. (2008) Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.. J Med Chem, 51 (7): (2115-2127). [PMID:18335976] [10.1021/jm701487t]
44. Wang H, Duffy RA, Boykow GC, Chackalamannil S, Madison VS.. (2008) Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.. J Med Chem, 51 (8): (2439-2446). [PMID:18363352] [10.1021/jm701519h]
45. Moloney GP, Angus JA, Robertson AD, Stoermer MJ, Robinson M, Wright CE, McRae K, Christopoulos A.. (2008) Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor.. Eur J Med Chem, 43 (3): (513-539). [PMID:17582659] [10.1016/j.ejmech.2007.04.007]
46. Wustrow DJ, Maynard GD, Yuan J, Zhao H, Mao J, Guo Q, Kershaw M, Hammer J, Brodbeck RM, Near KE, Zhou D, Beers DS, Chenard BL, Krause JE, Hutchison AJ.. (2008) Aminopyrazine CB1 receptor inverse agonists.. Bioorg Med Chem Lett, 18 (11): (3376-3381). [PMID:18448340] [10.1016/j.bmcl.2008.04.022]
47. Song KS, Lee SH, Chun HJ, Kim JY, Jung ME, Ahn K, Kim SU, Kim J, Lee J.. (2008) Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.. Bioorg Med Chem, 16 (7): (4035-4051). [PMID:18243711] [10.1016/j.bmc.2008.01.023]
48. Markt P, Feldmann C, Rollinger JM, Raduner S, Schuster D, Kirchmair J, Distinto S, Spitzer GM, Wolber G, Laggner C, Altmann KH, Langer T, Gertsch J.. (2009) Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.. J Med Chem, 52 (2): (369-378). [PMID:19143566] [10.1021/jm801044g]
49. Donohue SR, Pike VW, Finnema SJ, Truong P, Andersson J, Gulyás B, Halldin C.. (2008) Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors.. J Med Chem, 51 (18): (5608-5616). [PMID:18754613] [10.1021/jm800329z]
50. Donohue SR, Krushinski JH, Pike VW, Chernet E, Phebus L, Chesterfield AK, Felder CC, Halldin C, Schaus JM.. (2008) Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.. J Med Chem, 51 (18): (5833-5842). [PMID:18800770] [10.1021/jm800416m]
51. Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S.. (2009) Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.. J Med Chem, 52 (4): (1005-1017). [PMID:19161308] [10.1021/jm8011382]
52. Vachal P, Fletcher JM, Fong TM, Huang CC, Lao J, Xiao JC, Shen CP, Strack AM, Shearman L, Stribling S, Chen RZ, Frassetto A, Tong X, Wang J, Ball RG, Tsou NN, Hickey GJ, Thompson DF, Faidley TD, Nicolich S, Achanfuo-Yeboah J, Hora DF, Hale JJ, Hagmann WK.. (2009) 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.. J Med Chem, 52 (8): (2550-2558). [PMID:19320488] [10.1021/jm900063x]
53. Manera C, Saccomanni G, Adinolfi B, Benetti V, Ligresti A, Cascio MG, Tuccinardi T, Lucchesi V, Martinelli A, Nieri P, Masini E, Di Marzo V, Ferrarini PL.. (2009) Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.. J Med Chem, 52 (12): (3644-3651). [PMID:19435366] [10.1021/jm801563d]
54. Du W, Jewell JP, Lin LS, Colandrea VJ, Xiao JC, Lao J, Shen CP, Bateman TJ, Reddy VB, Ha SN, Shah SK, Fong TM, Hale JJ, Hagmann WK.. (2009) Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.. Bioorg Med Chem Lett, 19 (17): (5195-5199). [PMID:19632830] [10.1016/j.bmcl.2009.07.046]
55. Boström J, Olsson RI, Tholander J, Greasley PJ, Ryberg E, Nordberg H, Hjorth S, Cheng L.. (2010) Novel thioamide derivatives as neutral CB1 receptor antagonists.. Bioorg Med Chem Lett, 20 (2): (479-482). [PMID:20005704] [10.1016/j.bmcl.2009.11.125]
56. Fritch PC, McNaughton-Smith G, Amato GS, Burns JF, Eargle CW, Roeloffs R, Harrison W, Jones L, Wickenden AD.. (2010) Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.. J Med Chem, 53 (2): (887-896). [PMID:20020710] [10.1021/jm901497b]
57. Seo HJ, Kim MJ, Lee SH, Lee SH, Jung ME, Kim MS, Ahn K, Kim J, Lee J.. (2010) Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.. Bioorg Med Chem, 18 (3): (1149-1162). [PMID:20045337] [10.1016/j.bmc.2009.12.040]
58. Donohue SR, Varnäs K, Jia Z, Gulyás B, Pike VW, Halldin C.. (2009) Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors.. Bioorg Med Chem Lett, 19 (21): (6209-6212). [PMID:19767206] [10.1016/j.bmcl.2009.08.092]
59. Yan L, Huo P, Debenham JS, Madsen-Duggan CB, Lao J, Chen RZ, Xiao JC, Shen CP, Stribling DS, Shearman LP, Strack AM, Tsou N, Ball RG, Wang J, Tong X, Bateman TJ, Reddy VB, Fong TM, Hale JJ.. (2010) Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.. J Med Chem, 53 (10): (4028-4037). [PMID:20423086] [10.1021/jm100023j]
60. Lange JH, Attali A, van der Neut MA, Wals HC, Mulder A, Zilaout H, Duursma A, van Aken HH, van Vliet BJ.. (2010) Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists.. Bioorg Med Chem Lett, 20 (17): (4992-4998). [PMID:20688519] [10.1016/j.bmcl.2010.07.056]
61. Zhang Y, Gilliam A, Maitra R, Damaj MI, Tajuba JM, Seltzman HH, Thomas BF.. (2010) Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.. J Med Chem, 53 (19): (7048-7060). [PMID:20845959] [10.1021/jm1006676]
62. Trotter BW, Nanda KK, Burgey CS, Potteiger CM, Deng JZ, Green AI, Hartnett JC, Kett NR, Wu Z, Henze DA, Della Penna K, Desai R, Leitl MD, Lemaire W, White RB, Yeh S, Urban MO, Kane SA, Hartman GD, Bilodeau MT.. (2011) Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.. Bioorg Med Chem Lett, 21 (8): (2354-2358). [PMID:21420860] [10.1016/j.bmcl.2011.02.082]
63. Manley PJ, Zartman A, Paone DV, Burgey CS, Henze DA, Della Penna K, Desai R, Leitl MD, Lemaire W, White RB, Yeh S, Urban MO, Kane SA, Hartman GD, Bilodeau MT, Trotter BW.. (2011) Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.. Bioorg Med Chem Lett, 21 (8): (2359-2364). [PMID:21420857] [10.1016/j.bmcl.2011.02.078]
64. Donohue SR, Dannals RF, Halldin C, Pike VW.. (2011) N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors.. J Med Chem, 54 (8): (2961-2970). [PMID:21428406] [10.1021/jm2000536]
65. Carroll FI, Blough BE, Mascarella SW, Navarro HA, Eaton JB, Lukas RJ, Damaj MI.. (2010) Nicotinic acetylcholine receptor efficacy and pharmacological properties of 3-(substituted phenyl)-2β-substituted tropanes.. J Med Chem, 53 (23): (8345-8353). [PMID:21058665] [10.1021/jm100994w]
66. Turkman N, Shavrin A, Ivanov RA, Rabinovich B, Volgin A, Gelovani JG, Alauddin MM.. (2011) Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives.. Bioorg Med Chem, 19 (18): (5698-5707). [PMID:21872477] [10.1016/j.bmc.2011.07.062]
67. Mésangeau C, Amata E, Alsharif W, Seminerio MJ, Robson MJ, Matsumoto RR, Poupaert JH, McCurdy CR.. (2011) Synthesis and pharmacological evaluation of indole-based sigma receptor ligands.. Eur J Med Chem, 46 (10): (5154-5161). [PMID:21899931] [10.1016/j.ejmech.2011.08.031]
68. Fulp A, Bortoff K, Zhang Y, Seltzman H, Snyder R, Maitra R.. (2011) Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity.. Bioorg Med Chem Lett, 21 (19): (5711-5714). [PMID:21875798] [10.1016/j.bmcl.2011.08.032]
69. Teng H, Thakur GA, Makriyannis A.. (2011) Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.. Bioorg Med Chem Lett, 21 (19): (5999-6002). [PMID:21880487] [10.1016/j.bmcl.2011.07.017]
70. Yang Y, Miller KJ, Zhu Y, Hong Y, Tian Y, Murugesan N, Gu Z, O'Tanyi E, Keim WJ, Rohrbach KW, Johnghar S, Behnia K, Pelleymounter MA, Carlson KE, Ewing WR.. (2011) Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.. Bioorg Med Chem Lett, 21 (22): (6856-6860). [PMID:21962575] [10.1016/j.bmcl.2011.09.016]
71. Gijsen HJ, De Cleyn MA, Surkyn M, Van Lommen GR, Verbist BM, Nijsen MJ, Meert T, Wauwe JV, Aerssens J.. (2012) 5-sulfonyl-benzimidazoles as selective CB2 agonists-part 2.. Bioorg Med Chem Lett, 22 (1): (547-552). [PMID:22130134] [10.1016/j.bmcl.2011.10.091]
72. Sun X, Qiu J, Strong SA, Green LS, Wasley JW, Blonder JP, Colagiovanni DB, Stout AM, Mutka SC, Richards JP, Rosenthal GJ.. (2012) Structure-activity relationship of pyrrole based S-nitrosoglutathione reductase inhibitors: carboxamide modification.. Bioorg Med Chem Lett, 22 (6): (2338-2342). [PMID:22342142] [10.1016/j.bmcl.2012.01.047]
73. Zhang H, Tückmantel W, Eaton JB, Yuen PW, Yu LF, Bajjuri KM, Fedolak A, Wang D, Ghavami A, Caldarone B, Paterson NE, Lowe DA, Brunner D, Lukas RJ, Kozikowski AP.. (2012) Chemistry and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.. J Med Chem, 55 (2): (717-724). [PMID:22171543] [10.1021/jm201157c]
74. Fulp A, Bortoff K, Seltzman H, Zhang Y, Mathews J, Snyder R, Fennell T, Maitra R.. (2012) Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.. J Med Chem, 55 (6): (2820-2834). [PMID:22372835] [10.1021/jm201731z]
75. Chorvat RJ, Berbaum J, Seriacki K, McElroy JF.. (2012) JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities.. Bioorg Med Chem Lett, 22 (19): (6173-6180). [PMID:22959249] [10.1016/j.bmcl.2012.08.004]
76. Rizzo S, Tarozzi A, Bartolini M, Da Costa G, Bisi A, Gobbi S, Belluti F, Ligresti A, Allarà M, Monti JP, Andrisano V, Di Marzo V, Hrelia P, Rampa A.. (2012) 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents.. Eur J Med Chem, 58 (519-532). [PMID:23164658] [10.1016/j.ejmech.2012.10.045]
77. El Bakali J, Gilleron P, Body-Malapel M, Mansouri R, Muccioli GG, Djouina M, Barczyk A, Klupsch F, Andrzejak V, Lipka E, Furman C, Lambert DM, Chavatte P, Desreumaux P, Millet R.. (2012) 4-Oxo-1,4-dihydropyridines as selective CB₂ cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.. J Med Chem, 55 (20): (8948-8952). [PMID:23017078] [10.1021/jm3008568]
78. Yang P, Myint KZ, Tong Q, Feng R, Cao H, Almehizia AA, Alqarni MH, Wang L, Bartlow P, Gao Y, Gertsch J, Teramachi J, Kurihara N, Roodman GD, Cheng T, Xie XQ.. (2012) Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.. J Med Chem, 55 (22): (9973-9987). [PMID:23072339] [10.1021/jm301212u]
79. Annedi SC, Maddaford SP, Ramnauth J, Renton P, Rybak T, Silverman S, Rakhit S, Mladenova G, Dove P, Andrews JS, Zhang D, Porreca F.. (2012) Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine.. Eur J Med Chem, 55 (94-107). [PMID:22840695] [10.1016/j.ejmech.2012.07.006]
80. Plowright AT, Nilsson K, Antonsson M, Amin K, Broddefalk J, Jensen J, Lehmann A, Jin S, St-Onge S, Tomaszewski MJ, Tremblay M, Walpole C, Wei Z, Yang H, Ulander J.. (2013) Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.. J Med Chem, 56 (1): (220-240). [PMID:23227781] [10.1021/jm301511h]
81. Yang P, Wang L, Feng R, Almehizia AA, Tong Q, Myint KZ, Ouyang Q, Alqarni MH, Wang L, Xie XQ.. (2013) Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.. J Med Chem, 56 (5): (2045-2058). [PMID:23406429] [10.1021/jm3017464]
82. Rempel V, Fuchs A, Hinz S, Karcz T, Lehr M, Koetter U, Müller CE.. (2013) Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.. ACS Med Chem Lett, 4 (1): (41-45). [PMID:24900561] [10.1021/ml300235q]
83. Ouyang Q, Tong Q, Feng R, Myint KZ, Yang P, Xie XQ.. (2013) Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB2 Receptor Inverse Agonists.. ACS Med Chem Lett, 4 (4): (387-392). [PMID:24729834] [10.1021/ml3004236]
84. Manca I, Mastinu A, Olimpieri F, Falzoi M, Sani M, Ruiu S, Loriga G, Volonterio A, Tambaro S, Bottazzi ME, Zanda M, Pinna GA, Lazzari P.. (2013) Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake.. Eur J Med Chem, 62 (256-269). [PMID:23357307] [10.1016/j.ejmech.2012.12.056]
85. Madadi NR, Penthala NR, Brents LK, Ford BM, Prather PL, Crooks PA.. (2013) Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors.. Bioorg Med Chem Lett, 23 (7): (2019-2021). [PMID:23466226] [10.1016/j.bmcl.2013.02.025]
86. Rempel V, Volz N, Gläser F, Nieger M, Bräse S, Müller CE.. (2013) Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.. J Med Chem, 56 (11): (4798-4810). [PMID:23679955] [10.1021/jm4005175]
87. Germain AR, Carmody LC, Nag PP, Morgan B, Verplank L, Fernandez C, Donckele E, Feng Y, Perez JR, Dandapani S, Palmer M, Lander ES, Gupta PB, Schreiber SL, Munoz B.. (2013) Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.. Bioorg Med Chem Lett, 23 (6): (1834-1838). [PMID:23403082] [10.1016/j.bmcl.2013.01.025]
88. Mainolfi N, Powers J, Amin J, Long D, Lee W, McLaughlin ME, Jaffee B, Brain C, Elliott J, Sivak JM.. (2013) An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist.. J Med Chem, 56 (13): (5464-5472). [PMID:23738526] [10.1021/jm4004939]
89. Le Naour M, Akgün E, Yekkirala A, Lunzer MM, Powers MD, Kalyuzhny AE, Portoghese PS.. (2013) Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.. J Med Chem, 56 (13): (5505-5513). [PMID:23734559] [10.1021/jm4005219]
90. Huryn DM, Resnick LO, Wipf P.. (2013) Contributions of academic laboratories to the discovery and development of chemical biology tools.. J Med Chem, 56 (18): (7161-7176). [PMID:23672690] [10.1021/jm400132d]
91. Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML.. (2013) New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo.. J Med Chem, 56 (20): (7851-7861). [PMID:24050112] [10.1021/jm400766k]
92. Mahmoud MM, Ali HI, Ahn KH, Damaraju A, Samala S, Pulipati VK, Kolluru S, Kendall DA, Lu D.. (2013) Structure-activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1).. J Med Chem, 56 (20): (7965-7975). [PMID:24053617] [10.1021/jm4009828]
93. Petrov RR, Knight L, Chen SR, Wager-Miller J, McDaniel SW, Diaz F, Barth F, Pan HL, Mackie K, Cavasotto CN, Diaz P.. (2013) Mastering tricyclic ring systems for desirable functional cannabinoid activity.. Eur J Med Chem, 69 (881-907). [PMID:24125850] [10.1016/j.ejmech.2013.09.038]
94. Guerrero M, Poddutoori R, Urbano M, Peng X, Spicer TP, Chase PS, Hodder PS, Schaeffer MT, Brown S, Rosen H, Roberts E.. (2013) Discovery, design and synthesis of a selective S1P(3) receptor allosteric agonist.. Bioorg Med Chem Lett, 23 (23): (6346-6349). [PMID:24135724] [10.1016/j.bmcl.2013.09.075]
95. Morales P, Vara D, Goméz-Cañas M, Zúñiga MC, Olea-Azar C, Goya P, Fernández-Ruiz J, Díaz-Laviada I, Jagerovic N.. (2013) Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity.. Eur J Med Chem, 70 (111-119). [PMID:24141201] [10.1016/j.ejmech.2013.09.043]
96. Dossou KS, Devkota KP, Morton C, Egan JM, Lu G, Beutler JA, Moaddel R.. (2013) Identification of CB1/CB2 ligands from Zanthoxylum bungeanum.. J Nat Prod, 76 (11): (2060-2064). [PMID:24175626] [10.1021/np400478c]
97. Huang H, Guzman-Perez A, Acquaviva L, Berry V, Bregman H, Dovey J, Gunaydin H, Huang X, Huang L, Saffran D, Serafino R, Schneider S, Wilson C, DiMauro EF.. (2013) Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.. ACS Med Chem Lett, 4 (12): (1218-1223). [PMID:24900633] [10.1021/ml4003315]
98. González-Naranjo P, Pérez-Macias N, Campillo NE, Pérez C, Arán VJ, Girón R, Sánchez-Robles E, Martín MI, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Páez JA.. (2014) Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.. Eur J Med Chem, 73 (56-72). [PMID:24378710] [10.1016/j.ejmech.2013.11.026]
99. Khurana L, Ali HI, Olszewska T, Ahn KH, Damaraju A, Kendall DA, Lu D.. (2014) Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1).. J Med Chem, 57 (7): (3040-3052). [PMID:24635495] [10.1021/jm5000112]
100. Burstein SH.. (2014) The cannabinoid acids, analogs and endogenous counterparts.. Bioorg Med Chem, 22 (10): (2830-2843). [PMID:24731541] [10.1016/j.bmc.2014.03.038]
101. German N, Decker AM, Gilmour BP, Gay EA, Wiley JL, Thomas BF, Zhang Y.. (2014) Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).. J Med Chem, 57 (18): (7758-7769). [PMID:25162172] [10.1021/jm501042u]
102. Schroeder CE, Yao T, Sotsky J, Smith RA, Roy S, Chu YK, Guo H, Tower NA, Noah JW, McKellip S, Sosa M, Rasmussen L, Smith LH, White EL, Aubé J, Jonsson CB, Chung D, Golden JE.. (2014) Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus.. J Med Chem, 57 (20): (8608-8621). [PMID:25244572] [10.1021/jm501203v]
103. Lucchesi V, Hurst DP, Shore DM, Bertini S, Ehrmann BM, Allarà M, Lawrence L, Ligresti A, Minutolo F, Saccomanni G, Sharir H, Macchia M, Di Marzo V, Abood ME, Reggio PH, Manera C.. (2014) CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.. J Med Chem, 57 (21): (8777-8791). [PMID:25272206] [10.1021/jm500807e]
104. Guidetti R, Astles PC, Sanderson AJ, Hollinshead SP, Johnson MP, Chambers MG.. (2014) The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain.. Bioorg Med Chem Lett, 24 (24): (5572-5575). [PMID:25466177] [10.1016/j.bmcl.2014.11.006]
105. Han S, Thoresen L, Zhu X, Narayanan S, Jung JK, Strah-Pleynet S, Decaire M, Choi K, Xiong Y, Yue D, Semple G, Thatte J, Solomon M, Fu L, Whelan K, Al-Shamma H, Gatlin J, Chen R, Dang H, Pride C, Gaidarov I, Unett DJ, Behan DP, Sadeque A, Usmani KA, Chen C, Edwards J, Morgan M, Jones RM.. (2015) Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.. Bioorg Med Chem Lett, 25 (2): (322-326). [PMID:25488844] [10.1016/j.bmcl.2014.11.040]
106. Iwata Y, Ando K, Taniguchi K, Koba N, Sugiura A, Sudo M.. (2015) Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.. Bioorg Med Chem Lett, 25 (2): (236-240). [PMID:25499880] [10.1016/j.bmcl.2014.11.062]
107. Riether D, Zindell R, Wu L, Betageri R, Jenkins JE, Khor S, Berry AK, Hickey ER, Ermann M, Albrecht C, Ceci A, Gemkow MJ, Nagaraja NV, Romig H, Sauer A, Thomson DS.. (2015) Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.. Bioorg Med Chem Lett, 25 (3): (581-586). [PMID:25556092] [10.1016/j.bmcl.2014.12.019]
108. Bartolozzi A, Cirillo PF, Berry AK, Hickey ER, Thomson DS, Wu L, Zindell R, Albrecht C, Ceci A, Gemkow MJ, Nagaraja NV, Romig H, Sauer A, Riether D.. (2015) Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.. Bioorg Med Chem Lett, 25 (3): (587-592). [PMID:25575658] [10.1016/j.bmcl.2014.12.031]
109. Chorvat RJ.. (2013) Peripherally restricted CB1 receptor blockers.. Bioorg Med Chem Lett, 23 (17): (4751-4760). [PMID:23902803] [10.1016/j.bmcl.2013.06.066]
110. Takai K, Inoue Y, Konishi Y, Suwa A, Uruno Y, Matsuda H, Nakako T, Sakai M, Nishikawa H, Hashimoto G, Enomoto T, Kitamura A, Uematsu Y, Kiyoshi A, Sumiyoshi T.. (2014) Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists.. Bioorg Med Chem Lett, 24 (14): (3189-3193). [PMID:24856064] [10.1016/j.bmcl.2014.04.085]
111. El Bakali J, Muccioli GG, Body-Malapel M, Djouina M, Klupsch F, Ghinet A, Barczyk A, Renault N, Chavatte P, Desreumaux P, Lambert DM, Millet R.. (2015) Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.. ACS Med Chem Lett, 6 (2): (198-203). [PMID:25699149] [10.1021/ml500439x]
112. Wittgen HG, van den Heuvel JJ, van den Broek PH, Dinter-Heidorn H, Koenderink JB, Russel FG.. (2011) Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4.. Drug Metab Dispos, 39 (7): (1294-1302). [PMID:21511945] [10.1124/dmd.110.037812]
113. Radwan MM, ElSohly MA, El-Alfy AT, Ahmed SA, Slade D, Husni AS, Manly SP, Wilson L, Seale S, Cutler SJ, Ross SA.. (2015) Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.. J Nat Prod, 78 (6): (1271-1276). [PMID:26000707] [10.1021/acs.jnatprod.5b00065]
114. Han S, Zhang FF, Qian HY, Chen LL, Pu JB, Xie X, Chen JZ.. (2015) Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.. J Med Chem, 58 (15): (5751-5769). [PMID:26151231] [10.1021/acs.jmedchem.5b00227]
115. Kleigrewe K, Almaliti J, Tian IY, Kinnel RB, Korobeynikov A, Monroe EA, Duggan BM, Di Marzo V, Sherman DH, Dorrestein PC, Gerwick L, Gerwick WH.. (2015) Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria.. J Nat Prod, 78 (7): (1671-1682). [PMID:26149623] [10.1021/acs.jnatprod.5b00301]
116. Nirogi R, Mohammed AR, Shinde AK, Bogaraju N, Gagginapalli SR, Ravella SR, Kota L, Bhyrapuneni G, Muddana NR, Benade V, Palacharla RC, Jayarajan P, Subramanian R, Goyal VK.. (2015) Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.. Eur J Med Chem, 103 (289-301). [PMID:26363507] [10.1016/j.ejmech.2015.08.051]
117. Lopez-Tapia F, Walker KA, Brotherton-Pleiss C, Caroon J, Nitzan D, Lowrie L, Gleason S, Zhao SH, Berger J, Cockayne D, Phippard D, Suttmann R, Fitch WL, Bourdet D, Rege P, Huang X, Broadbent S, Dvorak C, Zhu J, Wagner P, Padilla F, Loe B, Jahangir A, Alker A.. (2015) Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.. J Med Chem, 58 (21): (8413-8426). [PMID:26460788] [10.1021/acs.jmedchem.5b00365]
118. Yrjölä S, Parkkari T, Navia-Paldanius D, Laitinen T, Kaczor AA, Kokkola T, Adusei-Mensah F, Savinainen JR, Laitinen JT, Poso A, Alexander A, Penman J, Stott L, Anskat M, Irving AJ, Nevalainen TJ.. (2016) Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists.. Eur J Med Chem, 107 (119-132). [PMID:26575458] [10.1016/j.ejmech.2015.10.050]
119. Fulp A, Zhang Y, Bortoff K, Seltzman H, Snyder R, Wiethe R, Amato G, Maitra R.. (2016) Pyrazole antagonists of the CB1 receptor with reduced brain penetration.. Bioorg Med Chem, 24 (5): (1063-1070). [PMID:26827137] [10.1016/j.bmc.2016.01.033]
120. Huard K, Gosset JR, Montgomery JI, Gilbert A, Hayward MM, Magee TV, Cabral S, Uccello DP, Bahnck K, Brown J, Purkal J, Gorgoglione M, Lanba A, Futatsugi K, Herr M, Genung NE, Aspnes G, Polivkova J, Garcia-Irizarry CN, Li Q, Canterbury D, Niosi M, Vera NB, Li Z, Khunte B, Siderewicz J, Rolph T, Erion DM.. (2016) Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family.. J Med Chem, 59 (3): (1165-1175). [PMID:26734723] [10.1021/acs.jmedchem.5b01752]
121. Waszkielewicz AM, Gunia-Krzyżak A, Powroźnik B, Słoczyńska K, Pękala E, Walczak M, Bednarski M, Żesławska E, Nitek W, Marona H.. (2016) Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.. Bioorg Med Chem, 24 (8): (1793-1810). [PMID:26988801] [10.1016/j.bmc.2016.03.006]
122. Kinney WA, McDonnell ME, Zhong HM, Liu C, Yang L, Ling W, Qian T, Chen Y, Cai Z, Petkanas D, Brenneman DE.. (2016) Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.. ACS Med Chem Lett, 7 (4): (424-428). [PMID:27096053] [10.1021/acsmedchemlett.6b00009]
123. Matthews JM, McNally JJ, Connolly PJ, Xia M, Zhu B, Black S, Chen C, Hou C, Liang Y, Tang Y, Macielag MJ.. (2016) Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.. Bioorg Med Chem Lett, 26 (21): (5346-5349). [PMID:27671496] [10.1016/j.bmcl.2016.09.025]
124. Zhu B, Matthews JM, Xia M, Black S, Chen C, Hou C, Liang Y, Tang Y, Macielag MJ.. (2016) Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.. Bioorg Med Chem Lett, 26 (22): (5597-5601). [PMID:27671499] [10.1016/j.bmcl.2016.09.026]
125. Osman NA, Ligresti A, Klein CD, Allarà M, Rabbito A, Di Marzo V, Abouzid KA, Abadi AH.. (2016) Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.. Eur J Med Chem, 122 (619-634). [PMID:27448919] [10.1016/j.ejmech.2016.07.012]
126. Khurana L, Fu BQ, Duddupudi AL, Liao YH, Immadi SS, Kendall DA, Lu D.. (2017) Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB1.. J Med Chem, 60 (3): (1089-1104). [PMID:28059509] [10.1021/acs.jmedchem.6b01448]
127. Xia L, de Vries H, Lenselink EB, Louvel J, Waring MJ, Cheng L, Pahlén S, Petersson MJ, Schell P, Olsson RI, Heitman LH, Sheppard RJ, IJzerman AP.. (2017) Structure-Affinity Relationships and Structure-Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists.. J Med Chem, 60 (23): (9545-9564). [PMID:29111736] [10.1021/acs.jmedchem.7b00861]
128. Dolles D, Hoffmann M, Gunesch S, Marinelli O, Möller J, Santoni G, Chatonnet A, Lohse MJ, Wittmann HJ, Strasser A, Nabissi M, Maurice T, Decker M.. (2018) Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles.. J Med Chem, 61 (4): (1646-1663). [PMID:29400965] [10.1021/acs.jmedchem.7b01760]
129. Nguyen T, German N, Decker AM, Langston TL, Gamage TF, Farquhar CE, Li JX, Wiley JL, Thomas BF, Zhang Y.. (2017) Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.. J Med Chem, 60 (17): (7410-7424). [PMID:28792219] [10.1021/acs.jmedchem.7b00707]
130. Fakhouri L, Cook CD, Al-Huniti MH, Console-Bram LM, Hurst DP, Spano MBS, Nasrallah DJ, Caron MG, Barak LS, Reggio PH, Abood ME, Croatt MP.. (2017) Design, synthesis and biological evaluation of GPR55 agonists.. Bioorg Med Chem, 25 (16): (4355-4367). [PMID:28673732] [10.1016/j.bmc.2017.06.016]
131. Liu Z, Tian B, Chen H, Wang P, Brasier AR, Zhou J.. (2018) Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation.. Eur J Med Chem, 151 (450-461). [PMID:29649741] [10.1016/j.ejmech.2018.04.006]
132. Bertini S, Chicca A, Gado F, Arena C, Nieri D, Digiacomo M, Saccomanni G, Zhao P, Abood ME, Macchia M, Gertsch J, Manera C.. (2017) Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.. Bioorg Med Chem, 25 (24): (6427-6434). [PMID:29079014] [10.1016/j.bmc.2017.10.015]
133. Amato GS, Manke A, Harris DL, Wiethe RW, Vasukuttan V, Snyder RW, Lefever TW, Cortes R, Zhang Y, Wang S, Runyon SP, Maitra R.. (2018) Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.. J Med Chem, 61 (10): (4370-4385). [PMID:29688015] [10.1021/acs.jmedchem.7b01820]
134. Amato GS, Manke A, Vasukuttan V, Wiethe RW, Snyder RW, Runyon SP, Maitra R.. (2018) Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists.. Bioorg Med Chem, 26 (15): (4518-4531). [PMID:30077609] [10.1016/j.bmc.2018.07.043]
135. Thomas MG, De Rycker M, Cotillo Torrejon I, Thomas J, Riley J, Spinks D, Read KD, Miles TJ, Gilbert IH, Wyatt PG.. (2018) 2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' disease.. Bioorg Med Chem Lett, 28 (18): (3025-3030). [PMID:30104093] [10.1016/j.bmcl.2018.08.005]
136. Mugnaini C, Rabbito A, Brizzi A, Palombi N, Petrosino S, Verde R, Di Marzo V, Ligresti A, Corelli F.. (2019) Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease.. Eur J Med Chem, 161 (239-251). [PMID:30359820] [10.1016/j.ejmech.2018.09.070]
137. Amato G, Manke A, Wiethe R, Vasukuttan V, Snyder R, Yueh YL, Decker A, Runyon S, Maitra R.. (2019) Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.. J Med Chem, 62 (13): (6330-6345). [PMID:31185168] [10.1021/acs.jmedchem.9b00727]
138. Ghonim AE, Ligresti A, Rabbito A, Mahmoud AM, Di Marzo V, Osman NA, Abadi AH.. (2019) Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.. Eur J Med Chem, 180 (154-170). [PMID:31302448] [10.1016/j.ejmech.2019.07.002]
139. Li J, Ji J, Xu R, Li Z.. (2019) Indole compounds with N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation.. Medchemcomm, 10 (11): (1935-1947). [PMID:32952995] [10.1039/C9MD00173E]
140. Garai S, Kulkarni PM, Schaffer PC, Leo LM, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, Szczesniak AM, Denovan-Wright EM, Mackie K, Hohmann AG, Reggio PH, Laprairie RB, Thakur GA.. (2020) Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.. J Med Chem, 63 (2): (542-568). [PMID:31756109] [10.1021/acs.jmedchem.9b01142]
141. Amato G, Wiethe R, Manke A, Vasukuttan V, Snyder R, Runyon S, Maitra R.. (2019) Functionalized 6-(piperidin-1-yl)-8,9-diphenyl purines as inverse agonists of the CB1 receptor - SAR efforts towards selectivity and peripheralization.. Bioorg Med Chem, 27 (16): (3632-3649). [PMID:31301950] [10.1016/j.bmc.2019.07.002]
142. Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos R, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Jagerovic N.. (2016) Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.. J Med Chem, 59 (14): (6753-6771). [PMID:27309150] [10.1021/acs.jmedchem.6b00397]
143. Seltzman HH, Shiner C, Hirt EE, Gilliam AF, Thomas BF, Maitra R, Snyder R, Black SL, Patel PR, Mulpuri Y, Spigelman I.. (2016) Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.. J Med Chem, 59 (16): (7525-7543). [PMID:27482723] [10.1021/acs.jmedchem.6b00516]
144. Mostyn SN, Rawling T, Mohammadi S, Shimmon S, Frangos ZJ, Sarker S, Yousuf A, Vetter I, Ryan RM, Christie MJ, Vandenberg RJ.. (2019) Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.. J Med Chem, 62 (5): (2466-2484). [PMID:30714733] [10.1021/acs.jmedchem.8b01775]
145. Zhao C, Rakesh KP, Ravidar L, Fang WY, Qin HL.. (2019) Pharmaceutical and medicinal significance of sulfur (S^VI)-Containing motifs for drug discovery: A critical review.. Eur J Med Chem, 162 (679-734). [PMID:30496988] [10.1016/j.ejmech.2018.11.017]
146. Mugnaini C, Kostrzewa M, Bryk M, Mahmoud AM, Brizzi A, Lamponi S, Giorgi G, Ferlenghi F, Vacondio F, Maccioni P, Colombo G, Mor M, Starowicz K, Di Marzo V, Ligresti A, Corelli F.. (2020) Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo.. J Med Chem, 63 (13): (7369-7391). [PMID:32515588] [10.1021/acs.jmedchem.0c00595]
147. Jung YH, Yu J, Wen Z, Salmaso V, Karcz TP, Phung NB, Chen Z, Duca S, Bennett JM, Dudas S, Salvemini D, Gao ZG, Cook DN, Jacobson KA.. (2020) Exploration of Alternative Scaffolds for P2Y₁₄ Receptor Antagonists Containing a Biaryl Core.. J Med Chem, 63 (17): (9563-9589). [PMID:32787142] [10.1021/acs.jmedchem.0c00745]
148. Smil D, Wong JF, Williams EP, Adamson RJ, Howarth A, McLeod DA, Mamai A, Kim S, Wilson BJ, Kiyota T, Aman A, Owen J, Poda G, Horiuchi KY, Kuznetsova E, Ma H, Hamblin JN, Cramp S, Roberts OG, Edwards AM, Uehling D, Al-Awar R, Bullock AN, O'Meara JA, Isaac MB.. (2020) Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.. J Med Chem, 63 (17): (10061-10085). [PMID:32787083] [10.1021/acs.jmedchem.0c01199]
149. Zhang YM,Greco M,Le Blanc T,Lang W,Kauffman J,Masucci J,Murray WV,Demarest K,Macielag MJ. (2020) Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CBR Inverse Agonists.. ACS Med Chem Lett, 11 (12.0): (2504-2509). [PMID:33335674] [10.1021/acsmedchemlett.0c00495]
150. Panknin O,Wagenfeld A,Bone W,Bender E,Nowak-Reppel K,Fernández-Montalván AE,Nubbemeyer R,Bäurle S,Ring S,Schmees N,Prien O,Schäfer M,Friedrich C,Zollner TM,Steinmeyer A,Mueller T,Langer G. (2020) Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women.. J Med Chem, 63 (20): (11854-11881). [PMID:32960053] [10.1021/acs.jmedchem.0c01076]
151. Arena C,Gado F,Di Cesare Mannelli L,Cervetto C,Carpi S,Reynoso-Moreno I,Polini B,Vallini E,Chicca S,Lucarini E,Bertini S,D'Andrea F,Digiacomo M,Poli G,Tuccinardi T,Macchia M,Gertsch J,Marcoli M,Nieri P,Ghelardini C,Chicca A,Manera C. (2020) The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.. Eur J Med Chem, 208 (112858-112858). [PMID:33002735] [10.1016/j.ejmech.2020.112858]
152. Qiao CJ,Ali HI,Ahn KH,Kolluru S,Kendall DA,Lu D. (2016) Synthesis and biological evaluation of indole-2-carboxamides bearing photoactivatable functionalities as novel allosteric modulators for the cannabinoid CB1 receptor.. Eur J Med Chem, 121 (517-529). [PMID:27318976] [10.1016/j.ejmech.2016.05.044]
153. Alghamdi SS,Mustafa SM,Moore Ii BM. (2021) Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.. Bioorg Med Chem, 33 (116035-116035). [PMID:33550084] [10.1016/j.bmc.2021.116035]
154. Granchi C,Bononi G,Ferrisi R,Gori E,Mantini G,Glasmacher S,Poli G,Palazzolo S,Caligiuri I,Rizzolio F,Canzonieri V,Perin T,Gertsch J,Sodi A,Giovannetti E,Macchia M,Minutolo F,Tuccinardi T,Chicca A. (2021) Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors.. Eur J Med Chem, 209 (112857-112857). [PMID:33045662] [10.1016/j.ejmech.2020.112857]
155. and Pertwee, R G RG.. (1999) Cannabis and cannabinoids: pharmacology and rationale for clinical use.. Forschende Komplementarmedizin, [PMID:10575283]
156. Tsai, S J SJ, Wang, Y C YC and Hong, C J CJ.. (2000) Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia.. Psychiatric genetics, [PMID:11204352]
157. Ulfers, Amy L AL and 5 more authors.. (2002) Cannabinoid receptor-G protein interactions: G(alphai1)-bound structures of IC3 and a mutant with altered G protein specificity.. Protein science : a publication of the Protein Society, [PMID:12237474]
158. Ryberg, Erik E and 7 more authors.. (2005) Identification and characterisation of a novel splice variant of the human CB1 receptor.. FEBS letters, (3): [PMID:15620723]
159. Niehaus, Jason L JL and 11 more authors.. (2007) CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a.. Molecular pharmacology, [PMID:17895407]
160. Jourdan, Tony T and 13 more authors.. (2013) Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes.. Nature medicine, [PMID:23955712]
161. Shim, Joong-Youn JY, Ahn, Kwang H KH and Kendall, Debra A DA.. (2013) Molecular basis of cannabinoid CB1 receptor coupling to the G protein heterotrimer Gαiβγ: identification of key CB1 contacts with the C-terminal helix α5 of Gαi.. The Journal of biological chemistry, (8): [PMID:24092756]
162. Ibeas Bih, Clementino C and 5 more authors.. (2015) Molecular Targets of Cannabidiol in Neurological Disorders.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, [PMID:26264914]
163. Morales, Paula; Hurst, Dow P and Reggio, Patricia H.. Molecular Targets of the Phytocannabinoids: A Complex Picture.. Progress in the chemistry of organic natural products, [PMID:28120232]
164. Scheiner M, Dolles D, Gunesch S, Hoffmann M, Nabissi M, Marinelli O, Naldi M, Bartolini M, Petralla S, Poeta E, Monti B, Falkeis C, Vieth M, Hübner H, Gmeiner P, Maitra R, Maurice T, Decker M.. (2019) Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo.. J Med Chem, 62 (20): (9078-9102). [PMID:31609608] [10.1021/acs.jmedchem.9b00623]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

货号 (SKU)	包装规格	是否现货
Ab177882-100μg	100μg	现货
Ab177882-1mg	1mg	现货
Ab177882-5mg	5mg	现货
Ab177882-10mg	10mg	期货

Nimacimab (anti-CNR1), 大麻素 CB1 受体负异位调节剂的负异位调节剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Nimacimab (anti-CNR1), 大麻素 CB1 受体负异位调节剂的负异位调节剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器